Remicade (infliximab) denied for failing step therapy by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UHC Denied Remicade Under Step Therapy

UnitedHealthcare's Commercial Medical Benefit Drug Policy for infliximab (effective 02.01.2026) is a textbook biosimilar-preferred step protocol. Under HCPCS codes J1745, Q5103, Q5104, and Q5121, UHC designates Avsola and Inflectra as preferred, while Remicade and Renflexis are non-preferred. To obtain reference Remicade, you must clear one of three gates: (1) a documented 14-week trial of Inflectra or Avsola with minimal clinical response; (2) physician attestation that clinical response would be expected to be superior with Remicade; or (3) documented intolerance/contraindication/adverse event to the preferred biosimilar with attestation that the same event would not recur with Remicade. The denial almost always lands on gate (1) because OptumRx and the UHC medical benefit reviewer cannot find a clean 14-week biosimilar trial in the chart, or the chart shows partial response that the reviewer reclassifies as "adequate."

## Insurer-Specific Mechanics

UHC routes Part B/medical-benefit infliximab through Optum Specialty Pharmacy and OptumRx prior auth — not CVS Caremark, not Express Scripts. Appeals filed through the wrong channel die on intake. The PA decision letter must cite the exact UHC medical policy version; demand the 02.01.2026 Infliximab Medical Benefit Drug Policy PDF in your appeal record under 29 CFR §2560.503-1(h)(2)(iii) (full and fair review, access to all documents relied upon). For ERISA self-funded plans, also invoke 29 USC §1185d — the Consolidated Appropriations Act step-therapy override provisions where state law applies via the plan's choice-of-law.

## Winning Levers

The strongest path is gate (3): if the patient had infusion reactions, antibody-to-infliximab (ATI) formation, or loss of response on Inflectra/Avsola, attach the ATI/trough level labs and a physician attestation that switching back to a different biosimilar carries the same immunogenicity risk — biosimilar-to-biosimilar switching data is sparse, and UHC's own policy concedes the attestation pathway. If the patient is biologic-naive and UHC is forcing biosimilar-first, that is policy-compliant and not appealable on medical grounds; pivot instead to formulary exception under the plan's pharmacy benefit if Remicade is medically necessary (e.g., established stable disease on Remicade prior to UHC enrollment triggers 45 CFR §156.122 continuity protections for ACA-regulated plans).

For experimental/medical-necessity overlay denials, cite Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) — the plan bears the burden of producing the clinical evidence supporting its denial, not the member. For behavioral or NQTL parity overlays on multi-condition cases, 29 CFR §2590.712 governs.

Tactical tip: Request the case-specific OptumRx clinical review notes (not just the denial letter) under 29 CFR §2560.503-1 within 30 days — UHC reviewers frequently miscategorize "minimal response" vs. "partial response," and the raw notes expose the error. Then file a Level 1 appeal with a peer-to-peer scheduled within 72 hours of denial.